Multiple Myeloma – Market Access and Reimbursement Insights Report – 2025
- Published Date : March 3, 2025
- Updated On : October 19, 2025
- Pages : 54
Multiple Myeloma Market Access and Reimbursement Insights
Thelansis’s “Multiple Myeloma Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Multiple Myeloma Overview
Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of clonal plasma cells in the bone marrow, which secrete significant quantities of non-functional proteins and immunoglobulins. Despite notable therapeutic advancements over many years, MM remains largely incurable. These hyperproliferative differentiated B-lymphocytes can produce various types of immunoglobulins (Ig), with IgG and IgA being the most common and IgD to a lesser extent. Typically, these abnormal plasma cells primarily grow within the bone marrow, with only a small fraction of patients initially showing extramedullary disease. Most patients experience relapses during treatment, progress to a refractory state, and cease to respond to therapy within 60 days of their last treatment: a grim prognosis and a high likelihood of relapse mark this. Additionally, with each subsequent relapse, patients endure progressively shorter periods of progression-free survival (PFS). For instance, PFS for first-line patients is around 18 months, but by the fourth line of therapy, it dwindles to a mere 4.7 months.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.
*Survey and interview discussion guide are customized based on client requirements
Deliverables format:
- PowerPoint presentation
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
- Market access and reimbursement for current therapies
- Coverage on plans
- Market access restrictions
- Rebates and contracting
- Factors influencing formulary access
- HEOR requirements and influence, etc.
- Expected market access and reimbursement for key emerging therapies
- Level of awareness
- Anticipated coverage on plans
- Factors that would improve market access
- Pricing, etc.
- Impact on brand use
- Key factors driving and limiting brand use
- Best and worst performers on market access, etc.
- Evolving environment
- Payer expectations from emerging therapies
- New policies and their expected impact, etc.
- Advise to drug manufacturers and developers
Multiple Myeloma Market Access and Reimbursement Insights
Thelansis’s “Multiple Myeloma Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Multiple Myeloma Overview
Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of clonal plasma cells in the bone marrow, which secrete significant quantities of non-functional proteins and immunoglobulins. Despite notable therapeutic advancements over many years, MM remains largely incurable. These hyperproliferative differentiated B-lymphocytes can produce various types of immunoglobulins (Ig), with IgG and IgA being the most common and IgD to a lesser extent. Typically, these abnormal plasma cells primarily grow within the bone marrow, with only a small fraction of patients initially showing extramedullary disease. Most patients experience relapses during treatment, progress to a refractory state, and cease to respond to therapy within 60 days of their last treatment: a grim prognosis and a high likelihood of relapse mark this. Additionally, with each subsequent relapse, patients endure progressively shorter periods of progression-free survival (PFS). For instance, PFS for first-line patients is around 18 months, but by the fourth line of therapy, it dwindles to a mere 4.7 months.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.
*Survey and interview discussion guide are customized based on client requirements
Deliverables format:
- PowerPoint presentation
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
- Market access and reimbursement for current therapies
- Coverage on plans
- Market access restrictions
- Rebates and contracting
- Factors influencing formulary access
- HEOR requirements and influence, etc.
- Expected market access and reimbursement for key emerging therapies
- Level of awareness
- Anticipated coverage on plans
- Factors that would improve market access
- Pricing, etc.
- Impact on brand use
- Key factors driving and limiting brand use
- Best and worst performers on market access, etc.
- Evolving environment
- Payer expectations from emerging therapies
- New policies and their expected impact, etc.
- Advise to drug manufacturers and developers
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)